9 Related NICE guidance
Published
-
Melanoma: assessment and management (2015) NICE guideline NG14
-
Suspected cancer: recognition and referral (2015) NICE guideline NG12
-
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (2014) NICE technology appraisal guidance 321
-
Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (2014) NICE interventional procedure guidance 478
-
Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (2013) NICE interventional procedure guidance 446
-
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma (2012) NICE technology appraisal guidance 269
-
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (2012) NICE technology appraisal guidance 268
-
Ambulight PDT for the treatment of non-melanoma skin cancer (2011) NICE medical technology guidance 6
-
Endoscopic radical inguinal lymphadenectomy (2011) NICE interventional procedure guidance 398
-
Skin cancer prevention (2011) NICE guideline PH32
-
Improving outcomes for people with skin tumours including melanoma (2010) Cancer service guidance
-
Photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions) (2006) NICE interventional procedure guidance 155
Under development
NICE is developing the following guidance (details available from the NICE website):
-
Melanoma (BRAF V600E mutation positive, unresectable, metastatic) – dabrafenib and trametinib. NICE technology appraisal guidance (publication expected August 2016)